In 2005, Liadis and colleagues found that caspase 3-deficient mice were protected from hyperglycemia following multiple low-dose streptozotocin (STZ) treatment, and this was related to reduced β-cell loss (Liadis et al. 2005). This evidence concerns the gene CASP3 and Hyperglycemia.